Please login to the form below
Rigel
This page shows the latest Rigel news and features for those working in and with pharma, biotech and healthcare.
Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors
Rigel already has ongoing pre-clinical activities with its lead CNS penetrant RIPK1 inhibitor candidates. ... We look forward to working with Rigel to advance its clinical development,” he added.
Latest news
-
Rigel and Ultragenyx claim approvals for rare drugs
The FDA gave the go-ahead to a pair of rare disease therapies this week, both marking the first-ever approvals for developers Rigel Pharmaceuticals and Ultragenyx. ... Rigel is also developing it for additional indications, including autoimmune
-
Rigel shaken after fostamatinib misses phase III trial target
Shares in Rigel Pharmaceuticals fell yesterday after it revealed its lead drug candidate fostamatinib had failed a phase III trial in chronic/persistent immune thrombocytopenia (ITP), a disease leading to reduced ... In August, Rigel reported the same 18
-
BMS buys immunotherapy specialist Flexus in $1.2bn deal
And signs new cancer research partnership with Rigel. Bristol-Myers Squibb will spend big to buy out Flexus Biosciences, a privately-held biotech focused on developing new anti-cancer therapeutics. . ... Meanwhile, this announcement was made on the same
-
Rigel plans job cuts in R&D restructure
The majority of the positions to be eliminated will be in drug discovery, with Rigel looking to focus its pipeline on three lead programmes in relatively late-stage development. ... Rigel said it expects to advance one of these two molecules into a phase
-
Rigel on the slide as asthma drug falls over
Share plummet after phase II failure of R343. Shares in US pharma company Rigel took a nosedive yesterday after an asthma drug in development at the company failed a phase II ... This was not the result we expected based on the collection of data we had
Rigel and Ultragenyx claim approvals for rare drugs
Rigel shaken after fostamatinib misses phase III trial target
BMS buys immunotherapy specialist Flexus in $1.2bn deal
More from news
Approximately 5 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Pharma deals in February 2015
February saw BMS further signal its intention to lead in this space announcing two simultaneous deals, the acquisition of Flexus Biosciences and a collaboration with Rigel. ... The earlier stage collaborative deal with Rigel is to develop and
-
Medius Deal Watch table for February 2015
Collaboration - develop and commercialise. 342. Rigel Pharmaceuticals/ BMS. Small molecule TGF beta receptor kinase inhibitors - immuno-oncology.
Pharma deals in February 2015
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Account Manager
-
Competitive Salary
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
-
Medical Editor
-
Competitive Salary
-
Associate Account Director
-
Competitive Salary
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
-
Account Management
-
Competitive Salary Offered
-
Senior Medical Writer
-
Competitive Salary
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
-
Senior Account Executive
-
Competitive Salary
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
-
Publications Director
-
Competitive Salary
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Merck & Co reveals plans for women’s health spinoff Organon
- Positive results for GSK/CureVac’s COVID-19 vaccine
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- Biogen and Capsigen to collaborate on gene therapies
- CanSinoBIO considers booster jab for COVID-19 vaccine
- Research Partnership’s MedTech Division appoints two Directors
- VMLY&Rx launches new payer agency in the US
- Biogen and Envisagenics to advance RNA splicing research for CNS diseases
- Positive results for GSK/CureVac’s COVID-19 vaccine
- New trial data for Keytruda in triple-negative breast cancer
- NICE recommends Keytruda for colorectal cancer patients with rare mutations
- Merck & Co reveals plans for women’s health spinoff Organon
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Why female mentorship is so powerful in pharma
- Positive results for GSK/CureVac’s COVID-19 vaccine
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Can protein degraders unlock ‘undruggable’ drug targets?
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
